{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:05:23Z","timestamp":1779271523534,"version":"3.51.4"},"posted":{"date-parts":[[2026,5,20]]},"group-title":"In Review","reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,12]]},"abstract":"<title>Abstract<\/title>\n                <p>Background\n HER3-targeted therapies are developing to clinical trials, while late pregnancy and earlier-onset breast neoplasm have increased the chance of overlap between childbearing age and cancer incidence. While more cancer patients of childbearing age may be exposed to these agents, considering HER3 expression and interactions within placental tissues is crucial for maternal and fetal safety.\nMethods\n Human placentas from healthy deliveries were used to isolate human amniotic epithelial cells (hAECs) and prepare amniotic membrane and umbilical cord sections. HER3 expression was analyzed in tissues, cells, and exosomes by multiplex immunofluorescence, flow cytometry, and immunoblot. The HER3-targeted nano-capsomere HPK2.0 and its nucleic acid-complexed form, HerLLAA, were synthesized and assessed by dynamic light scattering, and impact on hAEC viability was evaluated by metabolic assay. HPK uptake, release, and intracellular trafficking were examined using pulse-chase quantification and time-resolved imaging.\nResults\n Freshly isolated hAECs exhibited epithelial morphology and heterogeneous stemness and mesenchymal marker expression, with a substantial HER3-positive population. HER3 was strongly localized to the amniotic membrane epithelial layer and was enriched in the umbilical cord endothelium compared to vessel wall and Wharton\u2019s jelly. hAEC-derived extracellular vesicles displayed stable size profiles and contained HER3. HPK2.0 and HerLLAA formed stable nano-structures without inducing cytotoxicity on hAECs. Functionally, hAECs rapidly internalized HPK2.0 and HerLLAA and released it in a dose- and time-dependent manner, consistent with regulated intracellular trafficking rather than long-term retention.\nConclusions\n The amniotic membrane, umbilical cord, hAECs, and their exosomes express HER3 and actively interact with HER3-targeted nanotherapeutics. HPK2.0 and HerLLAA undergoes regulated uptake and release without cytotoxicity, underscoring both safety considerations during pregnancy and the potential for HER3-mediated placental and fetal drug delivery.<\/p>","DOI":"10.21203\/rs.3.rs-9107787\/v1","type":"posted-content","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:05:27Z","timestamp":1779267927000},"source":"Crossref","is-referenced-by-count":0,"title":["A Dual Role for the Placenta and Human Amniotic Epithelial Cells in HER3-Targeted Nanotherapy"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8853-4343","authenticated-orcid":false,"given":"Amirhesam","family":"Babajani","sequence":"first","affiliation":[{"name":"Cedars-Sinai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Ishaya","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Aceves","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelyda","family":"Gonzalez-Almeyda","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Wiesenthal","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravinder","family":"Abrol","sequence":"additional","affiliation":[{"name":"CSUN: California State University Northridge"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lali","family":"Medina-Kauwe","sequence":"additional","affiliation":[{"name":"Cedars-Sinai Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13046-022-02515-x","article-title":"HER3 in cancer: from the bench to the bedside","volume":"41","author":"Gandullo-S\u00e1nchez L","year":"2022","unstructured":"Gandullo-S\u00e1nchez L, Oca\u00f1a A, Pandiella A. HER3 in cancer: from the bench to the bedside. J Experimental Clin Cancer Res. 2022;41:310. https:\/\/doi.org\/10.1186\/s13046-022-02515-x.","journal-title":"J Experimental Clin Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.gendis.2024.101354","article-title":"HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway","volume":"12","author":"Desai O","year":"2025","unstructured":"Desai O, et al. HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway. Genes Dis. 2025;12:101354. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.gendis.2024.101354.","journal-title":"Genes Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/1541-7786.MCR-18-0341","article-title":"Endothelial cells promote colorectal cancer cell survival by activating the HER3-AKT pathway in a paracrine fashion","volume":"17","author":"Wang R","year":"2019","unstructured":"Wang R, et al. Endothelial cells promote colorectal cancer cell survival by activating the HER3-AKT pathway in a paracrine fashion. Mol Cancer Res. 2019;17:20\u20139.","journal-title":"Mol Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cam4.1995","article-title":"Targeting of the HER2\/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2\u2010positive breast cancer","volume":"8","author":"Watanabe S","year":"2019","unstructured":"Watanabe S, et al. Targeting of the HER2\/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2\u2010positive breast cancer. Cancer Med. 2019;8:1258\u201368.","journal-title":"Cancer Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"LMT48","DOI":"10.2217\/lmt-2020-0031","article-title":"HER3 expression and MEK activation in non-small-cell lung carcinoma","volume":"10","author":"Manickavasagar T","year":"2021","unstructured":"Manickavasagar T, et al. HER3 expression and MEK activation in non-small-cell lung carcinoma. Lung Cancer Manag. 2021;10:LMT48.","journal-title":"Lung Cancer Manag"},{"key":"ref6","author":"Bent AH","year":"2022","unstructured":"Bent AH et al. (American Society of Clinical Oncology, 2022)."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100790","DOI":"10.1016\/j.esmoop.2023.100790","article-title":"Targeting HER3 for cancer treatment: a new horizon for an old target","volume":"8","author":"Uliano J","year":"2023","unstructured":"Uliano J, Corvaja C, Curigliano G, Tarantino P. Targeting HER3 for cancer treatment: a new horizon for an old target. ESMO Open. 2023;8:100790. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.esmoop.2023.100790.","journal-title":"ESMO Open"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"101354","DOI":"10.1016\/j.gendis.2024.101354","article-title":"HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway","volume":"12","author":"Desai O","year":"2025","unstructured":"Desai O, et al. HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway. Genes Dis. 2025;12:101354. https:\/\/doi.org\/10.1016\/j.gendis.2024.101354.","journal-title":"Genes Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1200\/JCO.2024.42.16_suppl.3034","article-title":"YL202\/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial","volume":"42","author":"Cheng Y","year":"2024","unstructured":"Cheng Y, et al. YL202\/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial. J Clin Oncol. 2024;42:3034\u20133034. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3034.","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e15114","DOI":"10.1200\/JCO.2023.41.16_suppl.e15114","article-title":"Preclinical evaluation of novel HER3-targeting radioconjugates for the imaging and treatment of HER3-expressing cancers","volume":"41","author":"Beckford Vera D","year":"2023","unstructured":"Beckford Vera D, et al. Preclinical evaluation of novel HER3-targeting radioconjugates for the imaging and treatment of HER3-expressing cancers. J Clin Oncol. 2023;41:e15114\u201315114. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e15114.","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41565-025-01867-7","article-title":"Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth","volume":"20","author":"Alonso-Valenteen F","year":"2025","unstructured":"Alonso-Valenteen F, et al. Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth. Nat Nanotechnol. 2025;20:683\u201396. https:\/\/doi.org\/10.1038\/s41565-025-01867-7.","journal-title":"Nat Nanotechnol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.108737","article-title":"Abstract 2547 Mechanistic Insights into HPK: A Targeted Protein Delivery System for HER3-Driven Cancer Therapy","volume":"301","author":"Aceves J","year":"2025","unstructured":"Aceves J, Abrol R, Medina-Kauwe L. Abstract 2547 Mechanistic Insights into HPK: A Targeted Protein Delivery System for HER3-Driven Cancer Therapy. J Biol Chem. 2025;301. https:\/\/doi.org\/10.1016\/j.jbc.2025.108737.","journal-title":"J Biol Chem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1315495","author":"Osada T","year":"2017","unstructured":"Osada T et al. Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. Oncoimmunology 6, e1315495 (2017). https:\/\/doi.org\/10.1080\/2162402x.2017.1315495"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1200\/jco-24-02744","article-title":"Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy","volume":"43","author":"Steuer CE","year":"2025","unstructured":"Steuer CE, et al. Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. J Clin Oncol. 2025;43:2816\u201326. https:\/\/doi.org\/10.1200\/jco-24-02744.","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40265-025-02155-3","volume":"85","author":"Blair HA","year":"2025","unstructured":"Blair HA, Zenocutuzumab. First Approval Drugs. 2025;85:591\u20137. https:\/\/doi.org\/10.1007\/s40265-025-02155-3.","journal-title":"First Approval Drugs"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"11020","DOI":"10.1093\/nar\/gkz900","article-title":"HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo","volume":"47","author":"Alonso-Valenteen F","year":"2019","unstructured":"Alonso-Valenteen F, et al. HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo. Nucleic Acids Res. 2019;47:11020\u201343.","journal-title":"Nucleic Acids Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2017.12.024","article-title":"Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics","volume":"271","author":"Sims JD","year":"2018","unstructured":"Sims JD, et al. Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. J Controlled Release. 2018;271:127\u201338.","journal-title":"J Controlled Release"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s43856-022-00198-1","article-title":"Clinical trials and pregnancy","volume":"2","author":"Waitt C","year":"2022","unstructured":"Waitt C, et al. Clinical trials and pregnancy. Commun Med. 2022;2:132. https:\/\/doi.org\/10.1038\/s43856-022-00198-1.","journal-title":"Commun Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12905-024-03138-4","article-title":"Breast cancer and the steadily increasing maternal age: are they colliding?","volume":"24","author":"Londero AP","year":"2024","unstructured":"Londero AP, Bertozzi S, Xholli A, Cedolini C, Cagnacci A. Breast cancer and the steadily increasing maternal age: are they colliding? BMC Womens Health. 2024;24:286. https:\/\/doi.org\/10.1186\/s12905-024-03138-4.","journal-title":"BMC Womens Health"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"dev202088","DOI":"10.1242\/dev.202088","article-title":"Maternal-fetal cross-talk via the placenta: influence on offspring development and metabolism","volume":"150","author":"Kramer AC","year":"2023","unstructured":"Kramer AC, Jansson T, Bale TL, Powell TL. Maternal-fetal cross-talk via the placenta: influence on offspring development and metabolism. Development. 2023;150:dev202088.","journal-title":"Development"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.placenta.2018.11.003","article-title":"Fetal membrane architecture, aging and inflammation in pregnancy and parturition","volume":"79","author":"Menon R","year":"2019","unstructured":"Menon R, Richardson LS, Lappas M. Fetal membrane architecture, aging and inflammation in pregnancy and parturition. Placenta. 2019;79:40\u20135. 10.1016\/j.placenta.2018.11.003. https:\/\/doi.org\/https:\/\/doi.org\/.","journal-title":"Placenta"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207730","article-title":"Human Amniotic Epithelial Stem Cells: A Promising Seed Cell for Clinical Applications","volume":"21","author":"Qiu C","year":"2020","unstructured":"Qiu C, Ge Z, Cui W, Yu L, Li J. Human Amniotic Epithelial Stem Cells: A Promising Seed Cell for Clinical Applications. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21207730.","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.placenta.2017.06.344","article-title":"Vesicular uptake of macromolecules by human placental amniotic epithelial cells","volume":"57","author":"Sharshiner R","year":"2017","unstructured":"Sharshiner R, Brace RA, Cheung CY. Vesicular uptake of macromolecules by human placental amniotic epithelial cells. Placenta. 2017;57:137\u201343. 10.1016\/j.placenta.2017.06.344. https:\/\/doi.org\/https:\/\/doi.org\/.","journal-title":"Placenta"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"18148","DOI":"10.1038\/s41598-022-22562-w","article-title":"Anti-cancer effects of human placenta-derived amniotic epithelial stem cells loaded with paclitaxel on cancer cells","volume":"12","author":"Babajani A","year":"2022","unstructured":"Babajani A, Manzari-Tavakoli A, Jamshidi E, Tarasi R, Niknejad H. Anti-cancer effects of human placenta-derived amniotic epithelial stem cells loaded with paclitaxel on cancer cells. Sci Rep. 2022;12:18148. https:\/\/doi.org\/10.1038\/s41598-022-22562-w.","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/9780470151808.sc01e06s13","article-title":"Amnion epithelial cell isolation and characterization for clinical use","volume":"1","author":"Murphy S","unstructured":"Murphy S et al. Amnion epithelial cell isolation and characterization for clinical use. Curr Protoc Stem Cell Biol Chap. 1, Unit 1E.6 (2010). https:\/\/doi.org\/10.1002\/9780470151808.sc01e06s13","journal-title":"Curr Protoc Stem Cell Biol Chap"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers15123240","article-title":"Adenovirus-Derived Nano-Capsid Platforms for Targeted Delivery and Penetration of Macromolecules into Resistant and Metastatic Tumors","author":"Benhaghnazar RL","year":"2023","unstructured":"Benhaghnazar RL, Medina-Kauwe L. Adenovirus-Derived Nano-Capsid Platforms for Targeted Delivery and Penetration of Macromolecules into Resistant and Metastatic Tumors. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15123240.","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.64898\/2026.02.03.703292","author":"Sharma VK","year":"2026","unstructured":"Sharma VK et al. Next generation protein-corrole bio-assemblies provide effective tumoricidal treatment in a metastatic triple-negative breast cancer model. bioRxiv, 2026.2002.2003.703292 (2026). https:\/\/doi.org\/10.64898\/2026.02.03.703292"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s13104-017-2880-6","article-title":"Method and key points for isolation of human amniotic epithelial cells with high yield, viability and purity","volume":"10","author":"Motedayyen H","year":"2017","unstructured":"Motedayyen H, et al. Method and key points for isolation of human amniotic epithelial cells with high yield, viability and purity. BMC Res Notes. 2017;10:552. https:\/\/doi.org\/10.1186\/s13104-017-2880-6.","journal-title":"BMC Res Notes"},{"key":"ref29","first-page":"10","article-title":"Isolation and partial characterization of human amniotic epithelial cells: the effect of trypsin","volume":"6","author":"Tabatabaei M","year":"2014","unstructured":"Tabatabaei M, et al. Isolation and partial characterization of human amniotic epithelial cells: the effect of trypsin. Avicenna J Med Biotechnol. 2014;6:10\u201320.","journal-title":"Avicenna J Med Biotechnol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fbioe.2020.00180","article-title":"The Bottlenecks in Translating Placenta-Derived Amniotic Epithelial and Mesenchymal Stromal Cells Into the Clinic: Current Discrepancies in Marker Reports","author":"Ghamari S-H","year":"2020","unstructured":"Ghamari S-H, Abbasi-Kangevari M, Tayebi T, Bahrami S, Niknejad H. The Bottlenecks in Translating Placenta-Derived Amniotic Epithelial and Mesenchymal Stromal Cells Into the Clinic: Current Discrepancies in Marker Reports. Front Bioeng Biotechnol. 2020;8\u20132020. https:\/\/doi.org\/10.3389\/fbioe.2020.00180.","journal-title":"Front Bioeng Biotechnol"},{"key":"ref31","first-page":"1","article-title":"Emerging importance of HER3 in tumorigenesis and cancer therapy","author":"Garrett JT","year":"2025","unstructured":"Garrett JT, Tendler S, Feroz W, Kilroy MK, Yu H. Emerging importance of HER3 in tumorigenesis and cancer therapy. Nat Reviews Clin Oncol, 1\u201323 (2025).","journal-title":"Nat Reviews Clin Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/1078-0432.CCR-24-1762","article-title":"YAP Regulates HER3 Signaling\u2013Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers","volume":"31","author":"Katayama Y","year":"2025","unstructured":"Katayama Y, et al. YAP Regulates HER3 Signaling\u2013Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers. Clin Cancer Res. 2025;31:1127\u201341.","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.stem.2025.08.004","article-title":"Modeling the human maternal-fetal interface","volume":"32","author":"Bondarenko V","year":"2025","unstructured":"Bondarenko V, Turco MY. Modeling the human maternal-fetal interface. Cell Stem Cell. 2025;32:1321\u201345.","journal-title":"Cell Stem Cell"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","article-title":"Receptor-ligand interactions for optimized endocytosis in targeted therapies","volume":"380","author":"Sung Y","year":"2025","unstructured":"Sung Y, Choi Y, Kim ES, Ryu JH, Kwon IC. Receptor-ligand interactions for optimized endocytosis in targeted therapies. J Controlled Release. 2025;380:524\u201338. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.060.","journal-title":"J Controlled Release"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcpa.2007.04.006","article-title":"The influence of maternal immunization on infant immune responses","volume":"137","author":"Englund J","year":"2007","unstructured":"Englund J. The influence of maternal immunization on infant immune responses. J Comp Pathol. 2007;137:16\u2013S19.","journal-title":"J Comp Pathol"},{"key":"ref36","author":"Palmeira P","year":"2012","unstructured":"Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA. & Carneiro-Sampaio, M. IgG placental transfer in healthy and pathological pregnancies. Journal of Immunology Research 2012, 985646 (2012)."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.placenta.2021.12.018","article-title":"Maternal, fetal and placental regulation of placental iron trafficking","volume":"125","author":"O'Brien KO","year":"2022","unstructured":"O'Brien KO. Maternal, fetal and placental regulation of placental iron trafficking. Placenta. 2022;125:47\u201353. 10.1016\/j.placenta.2021.12.018. https:\/\/doi.org\/https:\/\/doi.org\/.","journal-title":"Placenta"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.omtn.2022.06.009","article-title":"Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1","volume":"29","author":"Davis SM","year":"2022","unstructured":"Davis SM, et al. Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1. Mol Ther Nucleic Acids. 2022;29:135\u201349. https:\/\/doi.org\/10.1016\/j.omtn.2022.06.009.","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e24291","DOI":"10.1161\/HYPERTENSIONAHA.124.24291","article-title":"Modulating placental functionality in preeclampsia with siRNA nanocomplexes","volume":"83","author":"Peng X","year":"2026","unstructured":"Peng X, Tan X, Dai L, Xia W, Wu Z. Modulating placental functionality in preeclampsia with siRNA nanocomplexes. Hypertension. 2026;83:e24291.","journal-title":"Hypertension"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijpharm.2018.05.001","article-title":"Efficient siRNA transfer to knockdown a placenta specific lncRNA using RGD-modified nano-liposome: A new preeclampsia-like mouse model","volume":"546","author":"Yu Q","year":"2018","unstructured":"Yu Q, et al. Efficient siRNA transfer to knockdown a placenta specific lncRNA using RGD-modified nano-liposome: A new preeclampsia-like mouse model. Int J Pharm. 2018;546:115\u201324. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.ijpharm.2018.05.001.","journal-title":"Int J Pharm"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.addr.2020.09.006","article-title":"Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy","volume":"160","author":"Figueroa-Espada CG","year":"2020","unstructured":"Figueroa-Espada CG, Hofbauer S, Mitchell MJ, Riley RS. Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy. Adv Drug Deliv Rev. 2020;160:244\u201361. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.addr.2020.09.006.","journal-title":"Adv Drug Deliv Rev"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9107787\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9107787\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:05:29Z","timestamp":1779267929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9107787\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":41,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9107787\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,5,20]]},"subtype":"preprint"}}